We are Not Dialing Back Our Warning on Valeant …
We are Dialing Back the Focus on Citron to Investigate and Report the Vast Spectrum of Claims Now Piling Up Against Valeant.
For over 14 years, Citron Research has been uncovering stock fraud and unique angles to stories that have gone either unnoticed or misunderstood by either Wall Street or the main street media. During that time, our work has preceded and predicted regulatory enforcement in over 50 instances, more than any other publication we know.
Just two weeks ago, nobody in the investment community had ever heard of Philidor … much less its "network"…
Citron Publishes the Smoking Gun!!
Price Target lowered to $50
Just four days ago in the world of Valeant, no one had ever heard of Philidor RX. Recent concerns about the company focused on its unsavory business practices of massive price raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development. But no one had discussed how these drugs were distributed….until this week.
Now Valeant has made new disclosures regarding its distribution channel, and they've led the company into a web of deception that … you have to read for yourselves.
Not Investable — Short Term Price Target $14 ·
It's NOT really an SaaS company.
In reality, it is a for-profit outsourced online degree provider founded almost eight years ago, yet still generates ~85% of revenues from only 4 clients.
- · Stock irrationally doubled due to economically inconsequential and highly controversial Yale deal that was denied accreditation on first try
- · 2U’s addressable market is tiny, there are dozens of competitors, and its contract economics are unattractive
- · Insider selling and recent capital raise suggest that management thinks stock is overvalued and likely to keep burning cash for next several years
- · Current valuation insane even when benched against actual SaaS companies … ~67%+ downside from current levels.
Valeant's Business Model is Broken:
Stock is Too Dangerous to Own: Short Term Price Target – $125
Over the past two weeks, shares of Valeant (NYSE:VRX) took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders. In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them.
Look no further Senator — Citron has done the work.
Over the past two weeks, shares of Valeant took a steep decline over concerns of price gouging that was recently expressed by Presidential hopeful Senator Bernie Sanders. In his plea for a subpoena of Valeant Sen. Sanders would like to see all communication regarding the price hikes and the reasons behind them. Look no further Senator — Citron has done the work.
Investors, Politicians, and Concerned Citizens must note that Valeant raised the prices on the two key heart drugs in question the very next day after they acquired them … just to cover up for a bad quarter.
Here's the proof — all done without wasting taxpayer money on a hearing.
The Real Risk to the US Healthcare System is when Health Care Costs are controlled by Hedge Fund Billionaires
How Pharmaceutical Pricing Runs Amok While U.S. Taxpayers Are Looted
As well as a major threat to the integrity of our entire healthcare system, Valeant (NYSE:VRX) is now the most devious three-cornered tax avoidance scheme we've ever seen.